Review





Similar Products

mek inhibitor pd98059  (TargetMol)
94
TargetMol mek inhibitor pd98059
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek Inhibitor Pd98059, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/PD98059/pmc13589945-120-15-19
Average 94 stars, based on 1 article reviews
mek inhibitor pd98059 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
mek pathway  (MedChemExpress)
99
MedChemExpress mek pathway
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek Pathway, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/SP600125/pm42546882-46-95-99
Average 99 stars, based on 1 article reviews
mek pathway - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
mek inhibitor mek1 2 inhibitor pd 0325901  (MedChemExpress)
96
MedChemExpress mek inhibitor mek1 2 inhibitor pd 0325901
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek Inhibitor Mek1 2 Inhibitor Pd 0325901, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/Mirdametinib/bio_rxiv__64898__2026__06__19__733436-285-28-40
Average 96 stars, based on 1 article reviews
mek inhibitor mek1 2 inhibitor pd 0325901 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
mek  (Huabio Inc)
86
Huabio Inc mek
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/akt+anti/pm42316185-123-36-40
Average 86 stars, based on 1 article reviews
mek - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
mek inhibitor u0126  (MedChemExpress)
98
MedChemExpress mek inhibitor u0126
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek Inhibitor U0126, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/U0126/pm42301608-51-25-29
Average 98 stars, based on 1 article reviews
mek inhibitor u0126 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
mek  (Solutia Inc)
86
Solutia Inc mek
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek, supplied by Solutia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/mek/us12655248-420-11-14
Average 86 stars, based on 1 article reviews
mek - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
mek erk pathway  (MedChemExpress)
98
MedChemExpress mek erk pathway
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek Erk Pathway, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/PD98059/pmc13394077-82-3-7
Average 98 stars, based on 1 article reviews
mek erk pathway - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
p mek  (ABclonal Biotechnology)
94
ABclonal Biotechnology p mek
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
P Mek, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/Phospho-MAP2K1-S217%2FMAP2K2-S221+Rabbit+pAb/pm42276991-242-16-17
Average 94 stars, based on 1 article reviews
p mek - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
mek inhibitor  (TargetMol)
95
TargetMol mek inhibitor
FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK <t>(PD98059)</t> on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.
Mek Inhibitor, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mek/Mirdametinib/pmc13283986-71-41-46
Average 95 stars, based on 1 article reviews
mek inhibitor - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK (PD98059) on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.

Journal: Acta Pharmaceutica Sinica. B

Article Title: Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β 1-mediated endothelial–mesenchymal transition

doi: 10.1016/j.apsb.2026.06.005

Figure Lengend Snippet: FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK (PD98059) on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.

Article Snippet: In the other series of experiments, HUVECs were pretreated with FAK inhibitor GSK2256098 (#T2281, Topscience), MEK inhibitor PD98059 (#T2623, Topscience), ALK inhibitor SB431542 (#T1726, Topscience) for 30 min, or pretreated with Integrin β 1 antibody (#MAB17781, R&D Systems) for 6 h, followed by treatment with FGL1.

Techniques: Activation Assay, Western Blot, Recombinant, Clinical Proteomics, Protein Concentration, Enzyme-linked Immunosorbent Assay, Immunofluorescence